Croda International Plc operates in the Pharmaceutical preparations sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Croda International Plc with three other
companies in this sector in the United Kingdom:
sales of £367.80 million [US$452.40 million]
of which 36%
was Licensing & Biotechnology),
(£664.95 million [US$817.90 million]
of which 100%
was Buprenorphine Based Drugs), and
Hikma Pharmaceuticals PLC
(£944.31 million [US$1.16 billion]
of which 49%
was Injectable Pharmaceuticals).
Croda International Plc reported sales of £1.08 billion (US$1.33 billion)
December of 2015.
increase of 3.4%
versus 2014, when the company's sales were £1.05 billion.
The sales level in 2015 was fairly close to the level five years ago: in 2010, Croda International Plc had sales
of £1.00 billion.
Sales of Life Sciences saw an increase
that was more than double the company's growth rate: sales were up
13.1% in 2015, from
£204.50 million to £231.30 million.
Not all segments of Croda International Plc experienced an increase in sales in 2015:
sales of Performance Technologies fell 0.1% to £354.80 million.